- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Next Gen Sequencing: ASCO Supports FDA Initiative
While supporting the FDA's standards-based regulatory efforts to explore next generation sequencing tests as diagnostic tools, the American Society of Clinical Oncology warned against misinterpretation or over-interpretation of test results.
The American Society of Clinical Oncology (ASCO) has submitted comments to the FDA on its white paper, “Optimizing FDA’s Regulatory Oversight of Next Generation Sequencing Diagnostic Tests.” The Society expressed its support of the exploration of new regulatory strategies for next generation sequencing (NGS) diagnostic tests, given the tests’ potential to identify individuals at high risk for developing cancer and to support clinical decisions for those already diagnosed.
In the letter, ASCO stated its support for a standards-based approach to regulatory review of NGS tests that would not only ensure continued quality, but would also validate the tests for analytic performance. Although ASCO strongly recommended that regulation be implemented in such a manner as to ensure ongoing innovation in the field of molecular diagnostics development, as well as timely patient access to the new generation of molecular and genomic tests that can improve care, the Society recognized the harm failed tests can cause patients by recommending them for inappropriate and potentially harmful treatment.
Link to the news on ASCO's website:
Link to the letter submitted to the FDA:
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
